Cited by 2,969Hematopoietic Stem Cell TransplantationInflammatory Biomarkers in Disease PrognosisRenal Transplantation Outcomes and Treatments

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Open access

Sorror, Mohamed L., Maris, Michael B., Storb, Rainer, Baron, Frederic, Sandmaier, Brenda M., Maloney, David G., Storer, Barry·2005·Blood

DOI 10.1182/blood-2005-05-2004PMC PMC1895304

Open this paper in CoChat — free account Open PDF

Abstract

We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT). However, the sample size of patients with scores of 1 or more, captured by the CCI, did not exceed 35%. Further, some comorbidities were rarely found among patients who underwent HCT. Therefore, the current study was designed to (1) better define previously identified comorbidities using pretransplant laboratory data, (2) investigate additional HCT-related comorbidities, and (3) establish comorbidity scores that were suited for HCT. Data were collected from 1055 patients, and then randomly divided into training and validation sets. Weights were assigned to individual comorbidities according to their prognostic significance in Cox proportional hazard models. The new index was then validated. The new index proved to be more sensitive than the CCI since it captured 62% of patients with scores more than 0 compared with 12%, respectively. Further, the new index showed better survival prediction than the CCI (likelihood ratio of 23.7 versus 7.1 and c statistics of 0.661 versus 0.561, respectively, P < .001). In conclusion, the new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival. This index will be useful for clinical trials and patient counseling before HCT. (Blood. 2005;106: 2912-2919)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2005-05-2004

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Regression modelling strategies for improved prognostic prediction
Harrell, F. E., Lee, K. L., Califf, R. M., Pryor, D. B., & Rosati, R. A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030207 · Cited by 1,804
Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives
Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717
The pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
Storb, R. F., Deeg, H. J., Whitehead, J., Appelbaum, F. R., Beatty, P. G., Bensinger, W., Buckner, C. D., Clift, R. A., Doney, K., Farewell, V. T., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411
Self-citation
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
McSweeney, P. A., Niederwieser, D. W., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,386
Self-citation

Show all 62 references

Research works printed but not linked: 1

Lubke T, Monig SP, Schneider PM, Holscher AH, Bollschweiler E. Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer? [German]. Zentralblatt für Chirurgie.2003;128: 970-976.

Sorted by citations

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., Dinardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,430
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Lyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,457
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
Gooley, T. A., Chien, J. W., Pergam, S. A., Hingorani, S. R., Sorror, M. L., Boeckh, M., Martin, P. J., Sandmaier, B. M., Marr, K. A., Appelbaum, F. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004383 · Cited by 1,491
Self-citation
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
Armand, P. A., Kim, H. T., Logan, B. R., Wang, Z. P., Alyea, E. P., Kalaycio, M. E., Maziarz, R. T., Antin, J. H., Soiffer, R. J., Weisdorf, D. J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-552984 · Cited by 951
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
Taur, Y., Jenq, R. R., Perales, M.-A., Littmann, E. R., Morjaria, S., Ling, L., No, D., Gobourne, A., Viale, A., Dahi, P. B., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554725 · Cited by 885
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
Koreth, J., Schlenk, R. F., Kopecky, K. J., Honda, S., Sierra, J., Djulbegović, B., Wadleigh, M., DeAngelo, D. J., Stone, R. M., Sakamaki, H., et al. (2009) · JAMA · doi:10.1001/jama.2009.813 · Cited by 902
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
Peled, J. U., Gomes, A. L. C., Devlin, S. M., Littmann, E. R., Taur, Y., Sung, A. D., Weber, D., Hashimoto, D., Slingerland, A. E., Slingerland, J. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1900623 · Cited by 765
Therapeutic Advances in Acute Myeloid Leukemia
Burnett, A. K., Wetzler, M., & Löwenberg, B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1820 · Cited by 806
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichhorst, B. F., Robak, T., Montserrat, E., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.019 · Cited by 610
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Lyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 541
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
Holtan, S. G., DeFor, T. E., Lazaryan, A., Bejanyan, N., Arora, M., Brunstein, C. G., Blazar, B. R., MacMillan, M. L., & Weisdorf, D. J. (2015) · Blood · doi:10.1182/blood-2014-10-609032 · Cited by 501
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
Brunstein, C. G., Barker, J. N., Weisdorf, D. J., DeFor, T. E., Miller, J. S., Blazar, B. R., McGlave, P. B., & Wagner, J. E. (2007) · Blood · doi:10.1182/blood-2007-04-067215 · Cited by 500
T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
Bashey, A., Zhang, X., Sizemore, C. A., Manion, K., Brown, S. L., Holland, H. K., Morris, L. E., & Solomon, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3523 · Cited by 498
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichhorst, B., Hallek, M., & Dreyling, M. H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq180 · Cited by 456
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia
Klepin, H. D., Geiger, A. M., Tooze, J. A., Kritchevsky, S. B., Williamson, J. D., Pardee, T. S., Ellis, L. R., & Powell, B. L. (2013) · Blood · doi:10.1182/blood-2012-12-471680 · Cited by 427
Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
Sorror, M. L., Storb, R. F., Sandmaier, B. M., Maziarz, R. T., Pulsipher, M. A., Maris, M. B., Bhatia, R., Ostronoff, F., Deeg, H. J., Syrjala, K. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8157 · Cited by 424
Self-citation
Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study
Green, M. L., Leisenring, W. M., Xie, H., Mast, T. C., Cui, Y. A., Sandmaier, B. M., Sorror, M. L., Goyal, S., Özkök, S., Yi, J., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00289-6 · Cited by 420
Self-citation
Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Walter, R. B., Gooley, T. A., Wood, B. L., Milano, F., Fang, M., Sorror, M. L., Estey, E. H., Salter, A. I., Lansverk, E., Chien, J. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8121 · Cited by 405
Self-citation
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
Cornelissen, J. J., Gratwohl, A. A., Schlenk, R. F., Sierra, J., Bornhäuser, M., Juliusson, G., Ráčil, Z., Rowe, J. M., Russell, N. H., Mohty, M., et al. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.150 · Cited by 405
Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation
Sorror, M. L., Sandmaier, B. M., Storer, B. E., Maris, M. B., Baron, F., Maloney, D. G., Scott, B. L., Deeg, H. J., Appelbaum, F. R., & Storb, R. F. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7865 · Cited by 398
Self-citation
Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation
El-Jawahri, A. R., LeBlanc, T. W., Vandusen, H. B., Traeger, L. N., Greer, J. A., Pirl, W. F., Jackson, V. A., Telles, J., Rhodes, A., Spitzer, T. R., et al. (2016) · JAMA · doi:10.1001/jama.2016.16786 · Cited by 399
A disease risk index for patients undergoing allogeneic stem cell transplantation
Armand, P. A., Gibson, C. J., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., Ritz, J., Sorror, M. L., Lee, S. J., Deeg, H. J., et al. (2012) · Blood · doi:10.1182/blood-2012-03-418202 · Cited by 385
Self-citation
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
Snowden, J. A., Sánchez‐Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Cámara, R., Dolstra, H., Duarte, R. F., Glaß, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 400
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
Muranski, P. J., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R. W., & Restifo, N. P. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0666 · Cited by 358
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
Yoshizato, T., Nannya, Y., Atsuta, Y., Shiozawa, Y., Iijima‐Yamashita, Y., Yoshida, K., Shiraishi, Y., Suzuki, H., Nagata, Y., Sato, Y., et al. (2017) · Blood · doi:10.1182/blood-2016-12-754796 · Cited by 352
Acute Myeloid Leukemia: A Concise Review
Saultz, J. N., & Garzon, R. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5030033 · Cited by 363
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
Sureda, A. M., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., Farge, D., Gennery, A. R., Kröger, N. M., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.6 · Cited by 341
Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
Sorror, M. L., Giralt, S., Sandmaier, B. M., Lima, M. J. G. D., Shahjahan, M., Maloney, D. G., Deeg, H. J., Appelbaum, F. R., Storer, B. E., & Storb, R. F. (2007) · Blood · doi:10.1182/blood-2007-06-096966 · Cited by 327
Self-citation
Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR
Dehn, J. G., Spellman, S. R., Hurley, C. K., Shaw, B. E., Barker, J. N., Burns, L. J., Confer, D. L., Eapen, M., Fernández-Viña, M., Hartzman, R. J., et al. (2019) · Blood · doi:10.1182/blood.2019001212 · Cited by 326
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
Sorror, M. L., Sandmaier, B. M., Storer, B. E., Franke, G., Laport, G. G., Chauncey, T. R., Agura, E. D., Maziarz, R. T., Langston, A. A., Hari, P., et al. (2011) · JAMA · doi:10.1001/jama.2011.1558 · Cited by 320
Self-citation
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F. R., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 307
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Dreger, P., Döhner, H., Ritgen, M., Böttcher, S., Busch, R. M., Dietrich, S., Bunjes, D. W., Cohen, S., Schubert, J. E. A., Hegenbart, U., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275420 · Cited by 305
Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Lim, Z., Brand, R., Martino, R., van Biezen, A., Finke, J., Bacigalupo, A. P., Beelen, D. W., Devergié, A., Alessandrino, E. P., Willemze, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8073 · Cited by 299
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Thol, F. R., Gabdoulline, R. R., Liebich, A., Klement, P., Schiller, J., Kandziora, C., Hambach, L., Stadler, M., Koenecke, C., Flintrop, M., et al. (2018) · Blood · doi:10.1182/blood-2018-02-829911 · Cited by 301
Comorbidity in older adults with cancer
Williams, G. R., MacKenzie, A. R., Magnuson, A. M., Olin, R. L., Chapman, A. E., Mohile, S. G., Allore, H. G., Somerfield, M. R., Targia, V., Extermann, M., et al. (2015) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2015.12.002 · Cited by 298
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Muffly, L. S., Pasquini, M. C., Martens, M. J., Brazauskas, R., Zhu, X., Adekola, K., Aljurf, M. D., Ballen, K. K., Bajel, A. R., Baron, F., et al. (2017) · Blood · doi:10.1182/blood-2017-03-772368 · Cited by 297
Self-citation
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
Malcovati, L., Porta, M. G. D., Strupp, C., Ambaglio, I., Kuendgen, A., Nachtkamp, K., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044602 · Cited by 282
Individual Prediction of Heart Failure Among Childhood Cancer Survivors
Chow, E. J., Chen, Y., Kremer, L. C. M., Breslow, N. E., Hudson, M. M., Armstrong, G. T., Border, W. L., Feijen, E. A. M., Green, D. M., Meacham, L. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.1373 · Cited by 281
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
Sasaki, K., Ravandi, F., Kadia, T. M., Dinardo, C. D., Short, N. J., Borthakur, G. M., Jabbour, E. J., & Kantarjian, H. M. (2021) · Cancer · doi:10.1002/cncr.33458 · Cited by 280
Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
Sorror, M. L., Storer, B. E., Sandmaier, B. M., Maris, M. B., Shizuru, J. A., Maziarz, R. T., Agura, E. D., Chauncey, T. R., Pulsipher, M. A., McSweeney, P. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4757 · Cited by 279
Self-citation
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
Engelhardt, M. M., Domm, A.-S., Dold, S. M., Ihorst, G., Reinhardt, H., Zober, A., Hieke, S., Baayen, C., Müller, S. J., Einsele, H., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.162693 · Cited by 275
Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma
Burroughs, L. M., O’Donnell, P. V., Sandmaier, B. M., Storer, B. E., Luznik, L., Symons, H. J., Jones, R. J., Ambinder, R. F., Maris, M. B., Blume, K. G., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.08.014 · Cited by 265
Self-citation
Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation
Sorror, M. L., Storer, B. E., Sandmaier, B. M., Maloney, D. G., Chauncey, T. R., Langston, A. A., Maziarz, R. T., Pulsipher, M. A., McSweeney, P. A., & Storb, R. F. (2008) · Cancer · doi:10.1002/cncr.23375 · Cited by 265
Self-citation
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients
Muffly, L. S., Kocherginsky, M., Stock, W., Chu, Q., Bishop, M. R., Godley, L. A., Kline, J. P., Liu, H., Odenike, O. M., Larson, R. A., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.103655 · Cited by 255
Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease
Reshef, R., Luger, S. M., Hexner, E. O., Loren, A. W., Frey, N. V., Nasta, S. D., Goldstein, S. C., Stadtmauer, E. A., Smith, J., Bailey, S. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201248 · Cited by 254
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
Giles, F. J., Borthakur, G. M., Ravandi, F., Faderl, S. H., Verstovšek, S., Thomas, D. A., Wierda, W. G., Ferrajoli, A., Kornblau, S. M., Pierce, S. A., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06476.x · Cited by 248
Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation
Mohty, M., Labopin, M., Volin, L., Gratwohl, A. A., Socié, G., Esteve, J., Tabrizi, R., Nagler, A., Rocha, V., & on behalf of the Acute Leukemia Working Party of, E. B. M. T. (2010) · Blood · doi:10.1182/blood-2010-02-266551 · Cited by 246
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
Sehgal, A. R., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., Godwin, J. E., Reagan, P. M., Wagner‐Johnston, N. D., Essell, J. H., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00339-4 · Cited by 245
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
Porta, M. G. D., Malcovati, L., Strupp, C., Ambaglio, I., Kuendgen, A., Zipperer, E., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.033506 · Cited by 243
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Kasamon, Y. L., Bolaños‐Meade, J., Prince, G. T., Tsai, H., McCurdy, S. R., Kanakry, J. A., Rosner, G. L., Brodsky, R. A., Perica, K., Smith, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4777 · Cited by 239
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis
Scott, B. L., Sandmaier, B. M., Storer, B. E., Maris, M. B., Sorror, M. L., Maloney, D. G., Chauncey, T. R., Storb, R. F., & Deeg, H. J. (2005) · Leukemia · doi:10.1038/sj.leu.2404010 · Cited by 235
Self-citation
Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial
El-Jawahri, A. R., Traeger, L. N., Greer, J. A., Vandusen, H. B., Fishman, S. R., LeBlanc, T. W., Pirl, W. F., Jackson, V. A., Telles, J., Rhodes, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2800 · Cited by 234
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Lübbert, M., Rüter, B. H., Claus, R., Schmoor, C., Schmid, M., Germing, U., Kuendgen, A., Rethwisch, V., Ganser, A., Platzbecker, U., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.048231 · Cited by 232
Cotransplantation of Mesenchymal Stem Cells Might Prevent Death from Graft-versus-Host Disease (GVHD) without Abrogating Graft-versus-Tumor Effects after HLA-Mismatched Allogeneic Transplantation following Nonmyeloablative Conditioning
Baron, F., Lechanteur, C., Willems, É., Bruck, F., Baudoux, É., Seidel, L., Vanbellinghen, J.-F., Hafraoui, K., Lejeune, M., Gothot, A., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.01.011 · Cited by 229
Self-citation
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
Oran, B., Lima, M. J. G. D., Garcia‐Manero, G., Thall, P. F., Lin, R., Popat, U., Alousi, A. M., Hosing, C. M., Giralt, S. A., Rondón, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002544 · Cited by 222
Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen–Matched Unrelated and Related Donors
Stasi, A. D., Milton, D. R., Poon, L. M., Hamdi, A., Rondón, G., Chen, J. J., Pingali, S. R., Konopleva, M. Y., Kongtim, P., Alousi, A. M., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.08.013 · Cited by 219
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study
Sorror, M. L., Logan, B. R., Zhu, X., Rizzo, J. D., Cooke, K. R., McCarthy, P. L., Ho, V. T., Horowitz, M. M., & Pasquini, M. C. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.004 · Cited by 222
Self-citation
How I assess comorbidities before hematopoietic cell transplantation
Sorror, M. L. (2013) · Blood · doi:10.1182/blood-2012-09-455063 · Cited by 219
Self-citation
Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation
El‐Jawahri, A. R., Traeger, L. N., Kuzmuk, K., Eusebio, J. R., Vandusen, H. B., Shin, J. A., Keenan, T., Gallagher, E. R., Greer, J. A., Pirl, W. F., et al. (2015) · Cancer · doi:10.1002/cncr.29149 · Cited by 218
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
Walter, R. B., Gyurkocza, B., Storer, B. E., Godwin, C. D., Pagel, J. M., Buckley, S. A., Sorror, M. L., Wood, B. L., Storb, R. F., Appelbaum, F. R., et al. (2014) · Leukemia · doi:10.1038/leu.2014.173 · Cited by 217
Self-citation
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
Deschler-Baier, B., Ihorst, G., Platzbecker, U., Germing, U., März, E., de Figuerido, M., Fritzsche, K., Haas, P. S., Salih, H. R., Giagounidis, A. A. N., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.067892 · Cited by 214
Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation
Storb, R. F., Gyurkocza, B., Storer, B. E., Sorror, M. L., Blume, K. G., Niederwieser, D. W., Chauncey, T. R., Pulsipher, M. A., Petersen, F. B., Sahebi, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0247 · Cited by 213
Self-citation
Frailty and the management of hematologic malignancies
Abel, G. A., & Klepin, H. D. (2017) · Blood · doi:10.1182/blood-2017-09-746420 · Cited by 213
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
Gyurkocza, B., Storb, R. F., Storer, B. E., Chauncey, T. R., Lange, T., Shizuru, J. A., Langston, A. A., Pulsipher, M. A., Bredeson, C., Maziarz, R. T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1460 · Cited by 210
Self-citation
Hematopoietic stem cell transplantation-50 years of evolution and future perspectives
Henig, I., & Zuckerman, T. (2014) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10162 · Cited by 209
Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study
Cohen, S., Roy, J., Lachance, S., Delisle, J., Marinier, A., Busque, L., Roy, D., Barabé, F., Ahmad, I., Bambace, N. M., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30202-9 · Cited by 209
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
Spyridonidis, A., Labopin, M., Savani, B. N., Niittyvuopio, R., Blaise, D., Craddock, C., Socié, G., Platzbecker, U., Beelen, D. W., Milpied, N. J., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0803-y · Cited by 209
Self-citation
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Kanakry, C. G., Tsai, H., Bolaños‐Meade, J., Smith, B. D., Gojo, I., Kanakry, J. A., Kasamon, Y. L., Gladstone, D. E., Matsui, W. H., Borrello, I., et al. (2014) · Blood · doi:10.1182/blood-2014-07-587477 · Cited by 204
Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?
Horan, J., Logan, B. R., Agovi, A. M., Lazarus, H. M., Bacigalupo, A. A., Ballen, K. K., Bredeson, C., Carabasi, M. H., Gupta, V. K., Hale, G. A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5001 · Cited by 203
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Dreger, P., Schetelig, J., Andersen, N. S., Corradini, P., van Gelder, M., Gribben, J. G., Kimby, E. K., Michallet, M., Moreno, C., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586826 · Cited by 203
A Risk Score for Mortality after Allogeneic Hematopoietic Cell Transplantation
Parimon, T., Au, D. H., Martin, P. J., & Chien, J. W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200603210-00007 · Cited by 196
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
McCurdy, S. R., Kasamon, Y. L., Kanakry, C. G., Bolaños‐Meade, J., Tsai, H., Showel, M. M., Kanakry, J. A., Symons, H. J., Gojo, I., Smith, B. D., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.144139 · Cited by 193
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
Sorror, M. L., Storer, B. E., Maloney, D. G., Sandmaier, B. M., Martin, P. J., & Storb, R. F. (2007) · Blood · doi:10.1182/blood-2007-07-098483 · Cited by 192
Self-citation
Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States
Jacobson, C. A., Locke, F. L., Ma, L., Asubonteng, J. O., Hu, Z., Siddiqi, T., Ahmed, S., Ghobadi, A., Miklos, D. B., Lin, Y., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.026 · Cited by 194
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
Gisselbrecht, C., & Neste, É. V. D. (2018) · British Journal of Haematology · doi:10.1111/bjh.15412 · Cited by 188
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma
Rezvani, A. R., Storer, B. E., Maris, M. B., Sorror, M. L., Agura, E. D., Maziarz, R. T., Wade, J. C., Chauncey, T. R., Forman, S. J., Lange, T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5477 · Cited by 187
Self-citation
Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
Gagelmann, N., Ditschkowski, M., Bogdanov, R., Bredin, S., Robin, M., Cassinat, B., Shahswar, R., Thol, F. R., Heuser, M., Socié, G., et al. (2019) · Blood · doi:10.1182/blood-2018-12-890889 · Cited by 189
Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Alyea, E. P., Kim, H. T., Ho, V. T., Cutler, C. S., DeAngelo, D. J., Stone, R. M., Ritz, J., Antin, J. H., & Soiffer, R. J. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.06.003 · Cited by 186
Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia
Kerbauy, D. M. B., Gooley, T. A., Sale, G. E., Flowers, M. E. D., Doney, K., Georges, G. E., Greene, J. E., Linenberger, M. L., Petersdorf, E. W., Sandmaier, B. M., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.11.004 · Cited by 179
Self-citation
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
Porta, M. G. D., Alessandrino, E. P., Bacigalupo, A. P., Lint, M. T. V., Malcovati, L., Pascutto, C., Falda, M., Bernardi, M., Onida, F., Guidi, S., et al. (2014) · Blood · doi:10.1182/blood-2013-12-542720 · Cited by 183
Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
Sorror, M. L., Storer, B. E., Fathi, A. T., Gerds, A. T., Medeiros, B. C., Shami, P. J., Brunner, A. M., Sekeres, M. A., Mukherjee, S., Peña, E., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2714 · Cited by 178
Self-citation
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making
Ferrara, F., Barosi, G., Venditti, A., Angelucci, E., Gobbi, M., Pane, F., Tosi, P., Zinzani, P. L., & Tura, S. (2013) · Leukemia · doi:10.1038/leu.2012.303 · Cited by 178
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
Röllig, C., Thiede, C., Gramatzki, M., Aulitzky, W. E., Bodenstein, H., Bornhäuser, M., Platzbecker, U., Stuhlmann, R., Schuler, U. S., Soucek, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-267302 · Cited by 176
The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality
Hill, J. A., Mayer, B. T., Xie, H., Leisenring, W. M., Huang, M.-L. W., Stevens‐Ayers, T., Milano, F., Delaney, C. S., Sorror, M. L., Sandmaier, B. M., et al. (2017) · Blood · doi:10.1182/blood-2016-10-748426 · Cited by 176
Self-citation
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
German-Austrian AML Study Group (AMLSG), Nagel, G., Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3150-3 · Cited by 182
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison
Cornelissen, J. J., van der Holt, B., Verhoef, G. E. G., Veer, M. B. V., van Oers, M. H. J., Schouten, H. C., Ossenkoppele, G. J., Sonneveld, P., Maertens, J. A., Kooy, M. V. M., et al. (2008) · Blood · doi:10.1182/blood-2008-07-168625 · Cited by 173
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia
Marsh, J. C. W., Gupta, V. K., Lim, Z., Ho, A. Y. L., Ireland, R. M., Hayden, J., Potter, V. T., Koh, M., Islam, M. S., Russell, N. H., et al. (2011) · Blood · doi:10.1182/blood-2010-12-327536 · Cited by 170
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia
Etienne, A., Esterni, B., Charbonnier, A., Mozziconacci, J., Arnoulet, C., Coso, D., Puig, B., Gastaut, J., Maraninchi, D., & Vey, N. (2007) · Cancer · doi:10.1002/cncr.22537 · Cited by 170
Cell-based therapeutic strategies for multiple sclerosis
Scolding, N. J., Pasquini, M. C., Reingold, S. C., Cohen, J. A., Sclerosis:, I. C. O. C.-B. T. F. M., Atkins, H. L., Banwell, B., Bar‐Or, A., Bebo, B. F., Bowen, J. D., et al. (2017) · Brain · doi:10.1093/brain/awx154 · Cited by 177
Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated
Abboud, R., Keller, J., Slade, M., DiPersio, J. F., Westervelt, P., Rettig, M. P., Meier, S., Fehniger, T. A., Abboud, C. N., Uy, G. L., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.010 · Cited by 171
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
Gibson, C. J., Kim, H. T., Zhao, L., Murdock, H. M., Hambley, B., Ogata, A., Madero-Marroquin, R., Wang, S., Green, L., Fleharty, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02286 · Cited by 168
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions
Liu, H., Rich, E. S., Godley, L. A., Odenike, O. M., Joseph, L. J., Marino, S. R., Kline, J. P., Nguyen, V. H., Cunningham, J. M., Larson, R. A., et al. (2011) · Blood · doi:10.1182/blood-2011-08-372508 · Cited by 167
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study
Alessandrino, E. P., Porta, M. G. D., Bacigalupo, A. P., Malcovati, L., Angelucci, E., Lint, M. T. V., Falda, M., Onida, F., Bernardi, M., Guidi, S., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.011429 · Cited by 166
Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
Shouval, R., Labopin, M., Bondi, O., Mishan‐Shamay, H., Shimoni, A., Ciceri, F., Esteve, J., Giebel, S., Gorin, N. C., Schmid, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1339 · Cited by 168
Self-citation
Modified Charlson Comorbidity Index for predicting survival after liver transplantation
Volk, M. L., Hernandez, J. C., Lok, A. S.-F., & Marrero, J. A. (2007) · Liver Transplantation · doi:10.1002/lt.21172 · Cited by 157
A General Practitioner’s Guide to Hematopoietic Stem-cell Transplantation
Bazinet, A., & Popradi, G. (2019) · Current Oncology · doi:10.3747/co.26.5033 · Cited by 157
Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide
Castagna, L., Crocchiolo, R., Fürst, S., Bramanti, S., Cheikh, J. E., Sarina, B., Granata, A., Mauro, E., Faucher, C., Mohty, B., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.02.001 · Cited by 155
Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer
Chow, E. J., Chen, Y., Hudson, M. M., Feijen, E. A. M., Kremer, L. C. M., Border, W. L., Green, D. M., Meacham, L. R., Mulrooney, D. A., Ness, K. K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.8673 · Cited by 154

Authors: Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B.
Affiliations: University of Washington (US)
From the Fred Hutchinson Cancer Research Center, Seattle, WA; and the University of Washington, Seattle, WA.
ORCID: Sorror, Mohamed L.
Storb, Rainer
Sandmaier, Brenda M.
Maloney, David G.
Storer, Barry
Venue: Blood
Publisher: American Society of Hematology
Published: 2005-10-15
Volume: 106
Issue: 8
Pages: 2912-2919
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2005-05-2004
PMC: PMC1895304
OpenAlex: W2128812336
Cited by: 2,969
References: 62
Citations by year: 2026: 139 · 2025: 208 · 2024: 223 · 2023: 213 · 2022: 192 · 2021: 246 · 2020: 209 · 2019: 171 · 2018: 173 · 2017: 174 · 2016: 144 · 2015: 145 · 2014: 134 · 2013: 112 · 2012: 86
FWCI: 25.46
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
ORBi (University of Liège) (submittedVersion, other-oa)
Funders: Fred Hutchinson Cancer Research Center
University of Washington
National Heart, Lung, and Blood Institute (HL-36444, P01HL036444)
National Cancer Institute (CA 49605, CA18029, CA 15704+, K23CA092058, CA 78902, CA92058, P01CA049605, P30CA015704, P01CA018029, P01CA078902)
Topics: Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
Keywords: hematopoietic stem cell transplantation, allogeneic transplantation, comorbidity index, Charlson Comorbidity Index, risk assessment, non-relapse mortality, survival prediction, prognostic scoring
MeSH terms: Contraindications, Adolescent, Adult, Aged, Cause of Death, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Prognosis, Transplantation, Homologous, Reproducibility of Results, Comorbidity, Survival Rate, Proportional Hazards Models, Treatment Outcome, Risk Assessment, Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks